Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma

Research output: Contribution to journalResearch articleContributedpeer-review



Purpose: Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of treatment response to CAB. For this reason, known genomic drivers were examined to identify potential predictors of treatment response with CAB. Methods: Twenty mRCC patients receiving monotherapy (≥ first-line) with CAB were prospectively included. DNA was extracted from archived primary tumors or metastatic tissue. Targeted DNA sequencing was performed using a gene panel including 328 genes (QIAseq Targeted DNA V3 Panel, Qiagen). The variant evaluation was performed using Varsome. The endpoints were treatment-failure-free-survival (TFFS) to CAB. Results: 26% of patients received systemic RCC treatment as the primary option. Six patients were treated with CAB in first-line (1L) and 12 patients in ≥ 2L. The median follow-up after initiation of systemic treatment was 26.7 months (mo). The PBRM1 (7 alleles), SETD2 (7 alleles), VHL (11 alleles), and CHEK2 (14 alleles) genes were most frequently altered. The median time to TFFS was 10.5 mo (95% confidence interval (CI) 6.2–14.7 mo). There was a longer treatment response to CAB in patients with alterations of the SETD2 gene (SETD2 alteration median TFFS not reached vs. no SETD2 alterations 8.4 mo (95% CI 5.2–11.6 mo); p = 0.024). Conclusion: Pathogenic variant genes may indicate treatment response to systemic therapy in mRCC. Patients with alterations of the SETD2 gene show longer responses to CAB treatment.


Original languageEnglish
Article number94
Pages (from-to)1-6
Number of pages6
JournalWorld journal of urology
Issue number1
Publication statusPublished - 22 Feb 2024

External IDs

PubMed 38386122


ASJC Scopus subject areas


  • Cabozantinib, Genomic alterations, Metastatic renal cell carcinoma, Anilides, Pyridines, Kidney Neoplasms/drug therapy, Humans, Genomics, DNA, Carcinoma, Renal Cell/drug therapy

Library keywords